The F.D.A. Suspends Use of Glaxo Antibody Drug in the U.S.

Manufacturers said lab testing revealed that the authorized dosage of the drug was not sufficiently potent against BA.2.Manufacturers said lab testing revealed that the authorized dosage of the drug was not sufficiently potent against BA.2.Coronavirus (2019-nCoV), Coronavirus Omicron Variant, Drugs (Pharmaceuticals), Food and Drug Administration, GlaxoSmithKline PLCRead More